|
|
Nature Technology Corporation
is a biotechnology company that provides industry partners with world class technology platforms including safe and efficacious non-viral vectors (plasmids) and processes for gene therapy and DNA vaccination vector production. NTC also provides cost effective outsourcing of product development services including synthetic gene design, vector construction, plasmid DNA manufacturing and recombinant proteins.
|
| NTC Publications/Press 2010-2012 |
Growing Skin - Wound healing and tissue regeneration. http://science.kqed.org/quest/video/growing-skin/
Thermostable Tag (TST) protein expression system: engineering thermotolerant recombinant proteins and vaccines.
Luke, J., Carnes, A.E., Sun, P., Hodgson, C.P., Waugh, D.S., and Williams, J.A. J. Biotechnol. 151:242-50 (2011)
Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers,
Luke, J., Vincent, J.M., Du, S.X., Whalen, B., Leen, A., Hodgson, C.P., and Williams, J.A.. Gene Ther.18:334-343 (2011)
Plasmid DNA Fermentation Strain and Process-Specific Effects on Vector Yield, Quality and Transgene Expression,
Carnes, A.E., Luke, J.M., Vincent, J.M., Schukar, A., Anderson, S., Hodgson, C.P., Williams, J.A. Biotechnol. Bioeng. 108:354-63 (2011)
|
Critical design criteria for minimal antibiotic-free plasmid vectors necessary to combine robust RNA Pol II and Pol III-mediated eukaryotic expression with high bacterial production yields,
Carnes, A.E., Luke, J.M., Vincent, J.M., Anderson, S., Schukar, A, Hodgson, C.P., and Williams, J.A. J. Gene Medicine 12(10):818-31. (2010)
Vector Insert-Targeted Integrative Antisense Expression System for Plasmid Stabilization,
Luke, J.M., Carnes, A.E., Hodgson, C.P., Williams, J.A. Mol. Biotechnol. 47:43-49, (2011)
Coexpressed RIG-I Agonist Enhances Humoral Immune Response to Influenza DNA Vaccine,
Luke, J.M., Simon, G.G., Soderholm, J., Errett, J.S., August, J.T., Gale, J., Hodgson, C.P., Williams, J.A. J. Virol. 85:1370-83, (2011)
|
|
| April Webinar: |
 |
“Vector Design for Vaccine and Gene Therapy Applications"
|
| DNAvaccine.com Presents: Vector Design for Vaccine and Gene Therapy Applications with Dr. Jim Williams from Nature Technology (NTC) |
|
Press Releases:
Two more groups entering Phase I clinical trials with NTC vectors (below). See details by viewing the above webinar. |
Brisbane, Australia, 17th April, 2012
|
|
Allied Healthcare announces Coridon license to NTC's vector technology |
| ...NTC has specifically designed safe, minimized and antibiotic-free selection vectors, which offer superior expression of recombinant proteins in mammalian cells. These vectors have been designed to comply with US Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulatory guidance..... |
 |
| NTC's Vectors used in Immunomic Therapeutics Clinical Trial for Allergy DNA Vaccines |
| Biotechnology News: |
 |
Tech Notes:Apr 15, 2012 (Vol. 2,No. 80
High-Yield Plasmid DNA Production
Aaron E. Carnes, James A. Williams, Ph.D.
NTC's new Process Meets Quality, Economy, and Scale Requirements Needed for Future Products |
|
